Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
4.810
-0.080 (-1.64%)
At close: May 8, 2026, 4:00 PM EDT
4.790
-0.020 (-0.42%)
After-hours: May 8, 2026, 5:28 PM EDT
Bicycle Therapeutics Revenue
Bicycle Therapeutics had revenue of $887.00K in the quarter ending March 31, 2026, a decrease of -91.11%. This brings the company's revenue in the last twelve months to $63.50M, up 146.85% year-over-year. In the year 2025, Bicycle Therapeutics had annual revenue of $72.59M with 105.77% growth.
Revenue (ttm)
$63.50M
Revenue Growth
+146.85%
P/S Ratio
5.28
Revenue / Employee
$220,472
Employees
288
Market Cap
335.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 72.59M | 37.31M | 105.77% |
| Dec 31, 2024 | 35.28M | 8.30M | 30.76% |
| Dec 31, 2023 | 26.98M | 12.51M | 86.52% |
| Dec 31, 2022 | 14.46M | 2.77M | 23.65% |
| Dec 31, 2021 | 11.70M | 1.31M | 12.58% |
| Dec 31, 2020 | 10.39M | -3.41M | -24.72% |
| Dec 31, 2019 | 13.80M | 6.67M | 93.40% |
| Dec 31, 2018 | 7.14M | 5.08M | 246.41% |
| Dec 31, 2017 | 2.06M | - | - |
| Dec 31, 2016 | 0 | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 228.37M |
| Lineage Cell Therapeutics | 14.56M |
| Opus Genetics | 14.20M |
| Abeona Therapeutics | 5.82M |
| Compass Therapeutics | 850.00K |
| Silence Therapeutics | 559.00K |
| YD Bio | 510.36K |
| Inhibikase Therapeutics | 1.00 |
BCYC News
- 8 days ago - Bicycle Therapeutics price target lowered to $12 from $13 at Jefferies - TheFly
- 8 days ago - Bicycle Therapeutics reports Q1 EPS (87c), consensus (65c) - TheFly
- 8 days ago - Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - Business Wire
- 17 days ago - Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting - Business Wire
- 18 days ago - Bicycle Therapeutics announces updates from EphA2 pipeline at AACR meeting - TheFly
- 18 days ago - Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026 - Business Wire
- 4 weeks ago - Bicycle Therapeutics price target lowered to $12 from $13 at Morgan Stanley - TheFly
- 7 weeks ago - Bicycle Therapeutics price target lowered to $7 from $11 at RBC Capital - TheFly